Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/3860| Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation | |
| Liu Hongling. He Xi. Wang Yudong. Zhou Shuangnan. Zhang Dali. Zhu Jiye. He Qiang. Zhu Zhijun. Li Guangming. Sun Libo. Wang Jianli. Cheng Gregory. Liu Zhenwen. Lau George. | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| 10.1007/s12072-020-10043-z | |
| Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic. | |
| Hepatology International | |
| 2020 | |
| Artículo | |
| https://link.springer.com/content/pdf/10.1007/s12072-020-10043-z.pdf | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 1105369.pdf | 718.83 kB | Adobe PDF | Visualizar/Abrir |